BCG, 1 .0 mg of C. parvum, or 0.5 mg of MER intraperitoneally at varying intervals before injection of an intravenous bacterial challenge. Four days before challenge, 300 mg of cyclophosphamide per ml was given intraperitoneally. BCG (106 colony-forming units) reduced mortality due to S. aureus at pretreatment intervals of 3, 7, 14 , and 28 days. Isonicotinic acid hydrazide treatment eliminated the protective effect of the live BCG. C. parvum was as effective as BCG against S. aureus septicemia when given 3 days before infection, but lost most of its protective effect after that time. MER protected at doses as small as 0.25 mg when given 25 days prior to challenge. Both BCG and C. parvum exerted a protective effect against Candida albicans infection.
Animals infected with live mycobacteria, i.e., BCG, acquire resistance to a variety of heterologous pathogens, including Staphylococcus aureus (5) , Salmonella (7, 17) , and Herpesvirus hominis (10) , as well as to tuberculous infection. Other immunostimulators, such as methanol-extraction residue (MER) of BCG (23) (24) (25) and Corynebacterium parvum (1, 3) agents currently used in cancer immunotherapy, have also been reported to induce similar resistanceenhancing effects. Cancer patients treated with immunosuppressive drugs often develop serious bacterial and fungal diseases. Immunotherapeutic efforts with BCG, MER, and C. parvum attempt to restore antitumor specific and nonspecific immune functions to the host. Besides the potential antitumor benefits, it is possible that increased resistance to opportunistic bacterial and fungal diseases may be induced. In these investigations, several parameters of antibacterial and antifungal resistance teria Culture Collection, Saranac Lake, N.Y., prepared as previously described (18) , and stored frozen at -70 C. The concentration of the stock vaccine in colony-forming units was determined by the method of Rosenthal et al. (16) . Immediately before use, the vaccine was rapidly thawed in a 37 C water bath and diluted with phosphate-buffered 0.85% NaCl, pH 7.2, and injected intraperitoneally (i.p.). Controls received 0.1 ml of phosphate-buffered saline. Counts of viable BCG in the spleen were determined as previously described (18 (Fig. 1) .
Effect of cyclophosphamide. To measure the point of optimal immunosuppressive effect of the cyclophosphamide, a dose of 300 mg/kg was given i.p. to groups of mice. A decrease in the total leukocyte count reached its nadir by day 4 and gradually returned to normal by day 8 (Fig.  2) . There was a decrease in the spleen weight, which returned to normal after 1 (Table 1) .
Effect of isoniazid treatment on the protective ability of BCG. Isoniazid treatment started 1 day before BCG adminstration prevented the growth of viable BCG, as shown by culturing the spleen at day 14. No mycobacteria could be cultured at this time. Isonicotinic acid hydrazide treatment diminished the protective effect of BCG and lowered the survival rate to that of the group receiving isonicotinic acid hydrazide alone (P < 0.01). Isonicotinic acid hydrazide treatment alone exerted a small but significant effect (Fig. 4) .
Effect of BCG and C. parvum on C. albicans septicemia. Results of experiments in which C. albicans was the challenge organism are seen in Table 2 (21) , BCG and C. parvum were capable of prolonging the survival from intravenous challenges ofS. aureus and C. albicans. MER provided a similar protective effect against the S. aureus. Both the BCG and the C. parvum induced an early onset of protective capacity against S. aureus. However, there was a loss of efficacy in the C. parvum at the later periods. Live BCG was found to be the most effective. The elimination of this protective effect by isonicotinic acid hydrazide treatment and the decreased protection with lower doses of BCG suggest a requirement for an adequate antigenic mass of BCG. This conceivably could be provided by the continued multiplication of the organisms or by a sufficient number of dead organisms. The multiplication of the live BCG in vivo may explain its prolonged duration of action as compared to the nonreplicating agents.
Although the exact mechanism of protection is not known, there is substantial evidence to indicate nonspecific enhancement of the reticuloendothelial system by the three immunostimulators tested. Macrophages in BCG-treated animals clear intravenously injected colloidal carbon at an accelerated rate (20) , have increased intracellular killing of organisms (2), and contain increased concentrations of lysosomal enzymes (4 system-enhancing abilities of C. parvum have been well documented. One study (20) showed that C. parvum is comparable to BCG in nonspecific stimulation of the reticuloendothelial system. Weiss et al. has shown that MER can enhance carbon clearance, increase elimination of antigen and increase levels of macrophage lysosomal enzymes (24) .
The role of humoral antibodies in our model was not investigated, but Collins and Scott recently showed that C. parvum gave considerable protection in normal mice given lethal doses of Salmonella enteritidis. They found no evidence for any increases in antibody titers to the Salmonella (3). In a similar study with Salmonella typhimurium, BCG enhanced protection from infection with no effect on bactericidal antibodies (17) .
Infectious complications comprise the leading cause of morbidity and mortality in patients with acute leukemia (11, 12) . Postmortem examination of patients with hematologic malignancy showed that 79% had documented infections prior to death (11) . Gram-negative bacteria, especially Pseudomonas species, as well as C. albicans have been increasingly the cause of septicemia and death over the last decade (9) .
Studies on leukemic animals, germfree from birth, show that these rodents tolerate greater dosages of radiation and chemotherapy than conventional animals since they are more resistant to infection (14) .
Nonspecific immunotherapy with these preparations may reduce infections in immunodeficient patients, which may then enable these patients to undergo more intensive chemotherapy and radiation therapy. This prolonged survival of leukemic patients receiving BCG and chemotherapy may be due to such nonspecific immunostimulation (15, 22) . A detailed study of the incidence of infection and the total amount of chemotherapy received in these patients might provide further information.
The present experiments demonstrate that, under certain conditions, BCG, MER, and C. parvum can reduce mortality from infection in immunosuppressed animals. The mechanism of action has not been clearly defined. Whether there is a faster return to immunocompetence as a result of stimulation of cellular components of the reticuloendothelial system and circulating granulocytes remains to be determined.
